Literature DB >> 15622586

Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining.

Chung Rong Changchien1, Meng-Chi Wu, Wen-Sy Tasi, Reiping Tang, Jy-Ming Chiang, Jinn-Shiun Chen, Shiu-Feng Huang, Jeng-Yi Wang, Chien-Yuh Yeh.   

Abstract

PURPOSE: The aim of this study was to identify associated prognostic factors influencing the outcome of curative resection of rectal gastrointestinal stromal tumor. PATIENTS AND METHODS: Diagnostic immunohistochemical staining with CD34, CD117, S-100, desmin, and muscle-specific actin was performed in 46 consecutive patients with previously diagnosed rectal leiomyosarcoma who underwent curative resection from 1979 to 1999. CD44, Bcl-2, P53, and Ki-67 staining were performed on tumors rediagnosed as gastrointestinal stromal tumor for the prognostic evaluation.
RESULTS: There were 42 (91.3 percent) patients with rectal gastrointestinal stromal tumor (18 females and 24 males; mean age, 58.4 years). Twenty-nine patients underwent radical surgical resections, such as abdominoperineal resection or low anterior resection, whereas the other 13 patients underwent wide local excision, such as transrectal excision or Kraske's operation. Sixteen tumors were classified as high-grade gastrointestinal stromal tumors, and 26 as low-grade. No tumor had a positive P53 stain. Twenty-seven patients (64.3 percent) developed recurrence or metastasis postoperatively (median follow-up, 52 months). The one-year, two-year, and five-year disease-free survival rates were 90.2 percent, 76.7 percent, and 43.9 percent, respectively. Of these patients with recurrence, subsequent resections in 12 patients with local recurrence, transarterial tumor embolism or STI-571 chemotherapies in 3 patients with distant mestastases were performed. The one-year, two-year, and five-year overall survival rates were 97.4 percent, 94.3 percent, and 83.7 percent, respectively. Bcl-2 (P = 0.007) and histologic grade (P = 0.05) in disease-free survival analysis and age < 50 years (P = 0.03) and tumor size > 5 cm (P = 0.02) in overall survival analysis were independent prognostic factors. The group with wide local excision had a higher local recurrence rate than that of the radical resection group (77 percent vs. 31 percent, P = 0.006), despite smaller tumors (4.5 vs. 7.2 cm, P = 0.05). There was no difference in the incidence of distant metastasis between the two groups.
CONCLUSION: Younger age (< 50 years), higher histologic tumor grade, positive Bcl-2 status, and larger tumors (> 5 cm) were factors associated with significantly poorer prognoses for rectal gastrointestinal stromal tumor. Radical resection was superior to wide local excision in the prevention of local recurrence, but not that of distant metastases.

Entities:  

Mesh:

Year:  2004        PMID: 15622586     DOI: 10.1007/s10350-004-0687-8

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  22 in total

1.  Caecal gastrointestinal stromal tumor with perforation and obstruction.

Authors:  M R Sreevathsa
Journal:  Indian J Surg Oncol       Date:  2012-09-22

2.  Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data.

Authors:  Masayoshi Yasui; Toshimasa Tsujinaka; Masaki Mori; Tsuyoshi Takahashi; Yasuo Nakashima; Toshirou Nishida
Journal:  Surg Today       Date:  2017-04-18       Impact factor: 2.549

3.  Rare anorectal neoplasms: gastrointestinal stromal tumor, carcinoid, and lymphoma.

Authors:  Elizabeth A Peralta
Journal:  Clin Colon Rectal Surg       Date:  2009-05

Review 4.  Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors.

Authors:  Manabu Kaneko; Shigenobu Emoto; Koji Murono; Hirofumi Sonoda; Masaya Hiyoshi; Kazuhito Sasaki; Yasutaka Shuno; Takeshi Nishikawa; Toshiaki Tanaka; Keisuke Hata; Kazushige Kawai; Hiroaki Nozawa
Journal:  Surg Today       Date:  2018-11-15       Impact factor: 2.549

5.  Transvaginal resection of a rectal gastrointestinal stromal tumor.

Authors:  Masayasu Hara; Satoru Takayama; Atsushi Arakawa; Mikinori Sato; Takaya Nagasaki; Hiromitsu Takeyama
Journal:  Surg Today       Date:  2012-06-09       Impact factor: 2.549

6.  Colorectal gastrointestinal stromal tumor.

Authors:  A Amato
Journal:  Tech Coloproctol       Date:  2010-11       Impact factor: 3.781

7.  Prognostic significance of PTEN, Ki-67 and CD44s expression patterns in gastrointestinal stromal tumors.

Authors:  Yu-Mei Liang; Xiang-Hong Li; Wen-Mei Li; You-Yong Lu
Journal:  World J Gastroenterol       Date:  2012-04-14       Impact factor: 5.742

8.  Transanal endoscopic microsurgery as optimal option in treatment of rare rectal lesions: A single centre experience.

Authors:  Monica Ortenzi; Roberto Ghiselli; Maria Michela Cappelletti Trombettoni; Luca Cardinali; Mario Guerrieri
Journal:  World J Gastrointest Endosc       Date:  2016-09-16

9.  Anorectal gastrointestinal stromal tumors: a retrospective multicenter analysis of 15 cases emphasizing their high local recurrence rate and the need for standardized therapeutic approach.

Authors:  Abbas Agaimy; Nikolaos Vassos; Bruno Märkl; Norbert Meidenbauer; Jens Köhler; Johann Spatz; Werner Hohenberger; Florian Haller; Roland S Croner; Regine Schneider-Stock; Klaus Matzel
Journal:  Int J Colorectal Dis       Date:  2013-02-13       Impact factor: 2.571

10.  Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.

Authors:  Michael J Cavnar; Lin Wang; Vinod P Balachandran; Cristina R Antonescu; William D Tap; Mary Keohan; Sam Singer; Larissa Temple; Garrett M Nash; Martin R Weiser; Jose G Guillem; Julio Garcia Aguilar; Ronald P DeMatteo; Philip B Paty
Journal:  Ann Surg Oncol       Date:  2017-10-20       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.